ArticleBMC infectious diseases2026
Antibiotic consumption and prescription patterns in a tertiary care hospital in Karachi, Pakistan: a cross-sectional study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPakistan ranks third among low-middle-income countries (LMICs) in human antibiotic consumption. Moreover, it has alarmingly high antimicrobial resistance rates. Surveillance of antibiotic consumption rates can guide towards more responsible use. Our study aims to describe the antibiotic consumption and prescribing patterns in a tertiary care center in Karachi, Pakistan between 2016 and 2023.
methodsThis retrospective cross-sectional study was conducted at a tertiary care hospital in Karachi between 2016 and 2023. Data on antibiotic use was extracted from the hospital’s electronic medical records and pharmacy database. Antibiotic consumption was reported using the defined daily dose (DDD) per 1000 patient-days. Data was also extracted on types of antibiotics consumed and prescription patterns were assessed using WHO AWaRe classification.Watch antibiotics included fluoroquinolones, third-generation cephalosporins, piperacillin-tazobactam, carbapenems, and vancomycin, which require cautious use and early review. Reserve antibiotics included colistin, ceftazidime-avibactam, and tigecycline, which are considered to be last resort agents for confirmed or suspected multidrug-resistant infections. The Chi-Square trend analysis was used to compare the trend in consumption of the WHO AWaRe antibiotic groups. P-value of < 0.05 was considered significant.
resultsDuring the study period, there were 413,596 total admissions, with 67.3% receiving antibiotics during hospitalization. Over eight years, the average antibiotic consumption was 1128.7 DDD/1,000 patient-days, with the greatest in 2016 (1145 DDD/1000 patient-days) and the lowest in 2021 (1009 DDD/1000 patient-days). The top 5 antibiotics utilized were ceftriaxone, meropenem, piperacillin-tazobactam, vancomycin, and cefazolin. According to the WHO AWaRe Classification, Watch antibiotics were the most prescribed (68.8–73.9%), followed by Access antibiotics (58-63.9%), while Reserve antibiotics increased from 3.8% to 5.3% during the study period (p < 0.001).
conclusionIn conclusion, this study reveals that a high proportion of patients receive antibiotics during hospitalization, and the majority of these were from the Watch category. These findings highlight the need to complement AWaRe- and DDD-based surveillance with evaluations of prescribing appropriateness and expanded monitoring to better inform antimicrobial stewardship efforts. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.